Alnylam Pharmaceuticals Inc
ALNY
View Detailed Chart
465.890USD
-2.815-0.60%
Close 09/12, 16:00（ET）Quotes delayed by 15 min
61.02BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.60%
5 Days
+3.07%
1 Month
+5.23%
6 Months
+92.71%
Year to Date
+97.99%
1 Year
+75.63%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-12Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
32
analysts
Buy
Current Rating
435.613
Target Price
-6.50%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 116.72% year-on-year.
Undervalued
The company’s latest PE is -188.25, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 131.78M shares, decreasing 2.43% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 13.24M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.39.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Ticker SymbolALNY
CompanyAlnylam Pharmaceuticals Inc
CEODr. Yvonne L. Greenstreet, M.D.
Websitehttps://www.alnylam.com/
Related Instruments
-0.17%
-0.24%
-0.84%
-1.90%
-2.80%
-2.72%
+1.14%
-2.24%
-2.81%
-3.94%
-1.30%
-0.77%
-2.81%
-1.23%
-0.61%
-1.52%
+0.03%
-1.60%
-1.44%
-0.15%
